Navigation Links
OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
Date:10/17/2007

Latest Randomized Clinical Trial Results of First Pro-Healing Stent Also

Featured at Annual Symposium

HONG KONG, Oct. 18 /PRNewswire/ -- OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is the subject of several sessions about innovation in interventional cardiology strategies and device design at this year's Transcatheter Cardiovascular Therapeutics symposium, TCT 2007, which is set for Oct. 20-25 at the Washington Convention Center in Washington, D.C.

The line-up of sessions that feature the first pro-healing stent, which is an alternative to drug-eluting stents, includes:

- Interventional Strategies and Adjunct Pharmacology in ACS and AMI;

Should Specialized DES for AMI be Developed? Early Experience with EPC

Capture Technology; Jan Henk Dambrink, M.D., Ph.D., Department of

Cardiology, ISALA Klinieken, Hospital De Weezenlanden, Zwolle, The

Netherlands; 2:10 p.m. EDT on Oct. 21; Room 151B

- Innovative Devices and Futuristic Concepts: Novel Bare Metal and Drug-

Eluting Stents; The Genous Stent Coating with CD34 Antibodies to

Actively Capture Circulating EPCs: Design Parameters and Effects on

Healing and Thrombogenicity; Michael Kutryk, M.D., clinician scientist

and interventional cardiologist at St. Michael's Hospital, assistant

professor at the University of Toronto; Canada; 3:08 p.m. EDT on Oct.

21; Room 152A

In addition, the latest results from clinical trials of the Genous stent will be discussed by Robbert de Winter, M.D., Ph.D., principal investigator and director of the catheterization laboratory at the Academic Medical Center in Amsterdam. Specifically, de Winter will present:

- Updates from the HEALING studies, AMC "Real World" registry and TRIAS

trial; 4:36 p.m. EDT on Oct. 21; Ballroom C, 3rd floor

- A late-breaking report of six-month clinical outcomes from the TRIAS HR

pilot study: a prospective, randomized trial comparing the Genous stent

and a paclitaxel-eluting stent in lesions at high risk for restenosis;

12:45 p.m. EDT on Oct. 22; Main Arena

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody- coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products in more than 60 countries. For more information, visit http://www.OrbusNeich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
2. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
5. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
6. Pharmathenes Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimers Research
7. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimers Research
8. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
10. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... New York , January 23, 2017 ... Non-Invasive Prenatal Testing Market was valued at US$0.53 bn in ... expanding at a strong 17.50% CAGR between 2014 and 2022. The ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... Non-invasive ...
(Date:1/23/2017)... The global  anxiety disorders and depression treatment market  is ... incidence of depression worldwide is anticipated to drive the market growth in the ... demand for antidepressants in the recent years. Continue ... ... ...
(Date:1/23/2017)... SAN DIEGO , 23. Januar 2017  ResMed ... China ) und 3B Medical ( Winter ... sich auf eine Vereinbarung über die Beilegung aller globalen ... ist der Verkauf ihrer bestehenden Produkte im ... eine einmalige Zahlung an 3B leisten, um das in ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... A Northwestern Pennsylvania ... domain address. Alpine Springs Rehabilitation & Recovery Center’s new website can be found ... along with its redesigned and retooled website. The treatment center has also revamped ...
(Date:1/23/2017)... ... 2017 , ... Ultimate Medical Academy today announced the keynote ... March 23-25, 2017 in Tampa, and reminded educators and education leaders to submit ... Dr. Michelle R. Weise, executive director of the Sandbox Collaborative, the R&D arm ...
(Date:1/23/2017)... ... ... and plastic balance boards have been around since at least the 1950s and are a ... first and only balance board to use a patent-pending design featuring high-pressure inflation technology and ... as well as skill-level adjustable for all ages and abilities. The board can be ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... the premiere organization in North America for the scientific development, healthcare training and ... Annual Scientific Session, and its 2017 AAT Member Certification Qualification Courses for Technicians, ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... However, choosing the right method is paramount to success. Selecting an inappropriate measurement ... situations where multiple persons use the same equipment. Rare or expensive substances are ...
Breaking Medicine News(10 mins):